Calcitonin gene-related peptide (CGRP) belongs to a family of peptides (adrenomedullin, amylin and calcitonin), most of which have significant effects on the cardiovascular system [1] . CGRP is the most potent endogenous vasodilatory peptide and is the most studied of the peptides in this family [2] . CGRP and its receptors are widely distributed throughout the vascular system. Localization of i-CGRP and its receptors in the heart, correlates well with the postulated functions of this peptide (i.e., increase in heart rate, atrial contractility, and increase in coronary blood flow). CGRP and ADM have direct effects on capacitance blood vessels, and administration leads to peripheral vasodilation and reduced vascular resistance. Injection or an infusion of physiological doses of CGRP and ADM has both significant effects on the blood pressure; cardiac performance, and blood supply to critical organs. Effects of CGRP (and its antagonists) have been examined as potential therapeutic agents in controlling hypertension, cardiac failure, cardiac arrhythmia, migraine headaches, Renaud's syndrome, preeclampsia, etc. Animal studies have revealed that in the presence of progesterone, administration of CGRP can alleviate both premature delivery and preeclampsia-like syndrome. The role of CGRP as a potential therapeutic agent and its mechanism of actions in alleviating pregnancy-induced hypertension will be discussed in detail [3] .
